Literature DB >> 31396340

MiR-302a-5p suppresses cell proliferation and invasion in non-small cell lung carcinoma by targeting ITGA6.

Wei Chen1, Xibing Zhuang1, Ruixue Qi1, Tiankui Qiao1.   

Abstract

MicroRNA-302a-5p (miR-302a-5p) has been implicated in several cancers; however, its role in human non-small cell lung carcinoma (NSCLC) remains unknown. In this study, we showed that miR-302a-5p is downregulated in NSCLC tissues and cell lines. Cell Counting Kit-8 and 5-ethynyl-2'-deoxyuridine assays showed that overexpression of a miR-302a-5p mimic suppressed NSCLC cell proliferation, which was confirmed by the results of a cell cycle assay. Overexpression of miR-302a-5p also reduced the migration and invasion of NSCLC cells. Additionally, miR-302a-5p overexpression significantly inhibited NSCLC growth and metastasis in a mouse xenograft model. With regard to the underlying mechanism, integrin α6 (ITGA6) mRNA was shown to be a novel target of miR-302a-5p, and overexpression of ITGA6 attenuated the inhibitory effects of miR-302a-5p on the proliferation and migration of NSCLC cells. In clinical NSCLC samples, miR-302a-5p expression was negatively correlated with ITGA6 expression, which was high in the samples. Collectively, these results indicate that miR-302a-5p acts as a tumor suppressor in NSCLC by directly targeting ITGA6 mRNA and may be useful as a theranostic biomarker of NSCLC.

Entities:  

Keywords:  ITGA6; miR-302a-5p; motility; non-small cell lung carcinoma; proliferation

Year:  2019        PMID: 31396340      PMCID: PMC6684888     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  25 in total

Review 1.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

Review 2.  Clinical practice. Lung cancer screening.

Authors:  James L Mulshine; Daniel C Sullivan
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

3.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

4.  MicroRNA-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB.

Authors:  Zhou Yongchun; Tian Linwei; Wang Xicai; Ye Lianhua; Zhao Guangqiang; Yu Ming; Li Guanjian; Lei Yujie; Huang Yunchao
Journal:  Cancer Lett       Date:  2014-01-29       Impact factor: 8.679

Review 5.  Overview: studying integrins in vivo.

Authors:  Clifford A Lowell; Tanya N Mayadas
Journal:  Methods Mol Biol       Date:  2012

Review 6.  Epidermal growth factor receptor mutations in lung cancer.

Authors:  Sreenath V Sharma; Daphne W Bell; Jeffrey Settleman; Daniel A Haber
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

7.  MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway.

Authors:  Xin Yang; Lei Liang; Xiao-Fei Zhang; Hu-Liang Jia; Yi Qin; Xu-Chao Zhu; Xiao-Mei Gao; Peng Qiao; Yan Zheng; Yuan-Yuan Sheng; Jin-Wang Wei; Hai-Jun Zhou; Ning Ren; Qing-Hai Ye; Qiong-Zhu Dong; Lun-Xiu Qin
Journal:  Hepatology       Date:  2013-06-05       Impact factor: 17.425

8.  PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186.

Authors:  Hongli Li; Chonggao Yin; Baogang Zhang; Yonghong Sun; Lihong Shi; Ningbo Liu; Shujuan Liang; Shijun Lu; Yuqing Liu; Jin Zhang; Fengjie Li; Wentong Li; Fei Liu; Lei Sun; Yuliang Qi
Journal:  Carcinogenesis       Date:  2013-05-13       Impact factor: 4.944

9.  Kruppel-like factor-9 (KLF9) inhibits glioblastoma stemness through global transcription repression and integrin α6 inhibition.

Authors:  Mingyao Ying; Jessica Tilghman; Yingying Wei; Hugo Guerrero-Cazares; Alfredo Quinones-Hinojosa; Hongkai Ji; John Laterra
Journal:  J Biol Chem       Date:  2014-10-06       Impact factor: 5.157

10.  Tumour-suppressive microRNA-29s inhibit cancer cell migration and invasion by targeting laminin-integrin signalling in head and neck squamous cell carcinoma.

Authors:  T Kinoshita; N Nohata; T Hanazawa; N Kikkawa; N Yamamoto; H Yoshino; T Itesako; H Enokida; M Nakagawa; Y Okamoto; N Seki
Journal:  Br J Cancer       Date:  2013-10-03       Impact factor: 7.640

View more
  6 in total

1.  Genome-wide analysis of prognostic-related lncRNAs, miRNAs and mRNAs forming a competing endogenous RNA network in lung squamous cell carcinoma.

Authors:  Qiang Ju; Yan-Jie Zhao; Sai Ma; Xin-Mei Li; Heng Zhang; Shao-Qiang Zhang; Yuan-Ming Yang; Song-Xia Yan
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-30       Impact factor: 4.553

2.  Integrin α6 overexpression promotes lymphangiogenesis and lymphatic metastasis via activating the NF-κB signaling pathway in lung adenocarcinoma.

Authors:  Sijia Ren; Jing Wang; Anyi Xu; Jiaqian Bao; William C Cho; Jinrong Zhu; Jianfei Shen
Journal:  Cell Oncol (Dordr)       Date:  2022-01-13       Impact factor: 6.730

3.  Mesenchymal Stem Cell-Derived Exosomal microRNA-3940-5p Inhibits Colorectal Cancer Metastasis by Targeting Integrin α6.

Authors:  Tao Li; Yingchun Wan; Ziyuan Su; Jiayu Li; Minna Han; Changyu Zhou
Journal:  Dig Dis Sci       Date:  2020-07-15       Impact factor: 3.199

4.  Exosomal miR-126 blocks the development of non-small cell lung cancer through the inhibition of ITGA6.

Authors:  Mingjun Li; Qianqian Wang; Xiaofei Zhang; Ningning Yan; Xingya Li
Journal:  Cancer Cell Int       Date:  2020-12-15       Impact factor: 5.722

5.  Prognosis-related autophagy genes in female lung adenocarcinoma.

Authors:  Zhongxiang Liu; Koudong Zhang; Zhangyan Zhao; Zhu Qin; Haicheng Tang
Journal:  Medicine (Baltimore)       Date:  2022-01-07       Impact factor: 1.889

6.  Identification of Colon Cancer-Related RNAs Based on Heterogeneous Networks and Random Walk.

Authors:  Bolin Chen; Teng Wang; Jinlei Zhang; Shengli Zhang; Xuequn Shang
Journal:  Biology (Basel)       Date:  2022-07-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.